The notices it replaced
- Reissues: PAR-24-100 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- 2 steps back: PAR-21-083 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- 3 steps back: PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- 4 steps back: PAR-16-270 NIAID Clinical Trial Implementation Cooperative Agreement (U01)
- 5 steps back: PAR-13-151 NIAID Clinical Trial Implementation Cooperative Agreement (U01)
- 6 steps back: PAR-11-234 NIAID Clinical Trial Implementation Cooperative Agreement (U01)
- 7 steps back: PAR-10-186 NIAID Clinical Trial Implementation Cooperative Agreement (U01)
- 8 steps back: PAR-05-113 NIAID Clinical Trial Implementation (U01) Cooperative Agreement
Who won it before
99 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $117,984,150 in first-year total cost, median $1,088,316.
Most frequent study sections
- Special Emphasis Panel[ZAI1 MFH-M (M1)]7
- Special Emphasis Panel[ZAI1 LG-M (M1)]5
- Special Emphasis Panel[ZAI1 BLG-M (M1)]3
- Special Emphasis Panel[ZAI1 MSA-M (J1)]3
- Special Emphasis Panel[ZAI1 PA-I (M1)]3
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO10
- JOHNS HOPKINS UNIVERSITY8
- BOSTON CHILDREN'S HOSPITAL6
- VANDERBILT UNIVERSITY MEDICAL CENTER6
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST)1U01AI195193-01 · under PAR-24-100 | NAGGIE, SUSANNA | DUKE UNIVERSITY, NC | $3,411,692 | ZAI1 |
| 2025 | Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk2U01AI138897-06A1 · under PAR-24-100 | DURAND, CHRISTINE MARIESEGEV, DORRY L.TOBIAN, AARON A | JOHNS HOPKINS UNIVERSITY, MD | $1,683,861 | ZAI1 |
| 2025 | Phase 1 study of a SARS-CoV-2 vaccine adjuvanted via controlled biodistribution of mRNA encoding spike protein and IL-12p701U01AI191995-01 · under PAR-24-100 | BADEN, LINDSEY ROBERTDOWLING, DAVID JAMES | BOSTON CHILDREN'S HOSPITAL, MA | $1,673,641 | ZAI1 |
| 2025 | Phase 1 Randomized Double-Blind Placebo-Controlled Safety Study of MucoCept-CVN (Lactobacillus jensenii 1153-1666) Administered Vaginally to Healthy Women1U01AI186333-01 · under PAR-21-083 | COHEN, CRAIG RHEMMERLING, ANKE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,533,177 | ZAI1 |
| 2025 | SMART Use of Biologics in Chronic Rhinosinusitis with Nasal Polyposis1U01AI181696-01A1 · under PAR-24-100 | MULLIGAN, JENNIFER KONOPASMITH, TIMOTHY LSOLER, ZACHARY M | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $1,498,642 | ZAI1 |
| 2025 | EARLY SIGNALS OF THE TRANSITION FROM IMMUNE QUIESCENCE TO ACTIVATION IN THE LIVER ALLOGRAFT MICROENVIRONMENT AND IN THE CIRCULATION1U01AI189341-01 · under PAR-24-100 | FENG, SANDY | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,468,517 | ZAI1 |
| 2025 | Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector2U01AI125051-08 · under PAR-24-100 | WILLIAMS, DAVID A | BOSTON CHILDREN'S HOSPITAL, MA | $1,305,361 | ZAI1 |
| 2025 | Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial1U01AI192041-01 · under PAR-24-100 | GARCIA-PRATS, ANTHONY JOSEPH | UNIVERSITY OF WISCONSIN-MADISON, WI | $1,286,549 | ZAI1 |
| 2025 | Molecular determinants of vaccine-induced antibody durability1U01AI189332-01A1 · under PAR-24-100 | LEWIS, GEORGE KSAJADI, MOHAMMAD MOHSENI | UNIVERSITY OF MARYLAND BALTIMORE, MD | $777,495 | ZAI1 |
| 2025 | The impact of shigellosis and recommended treatment in children1U01AI179562-01A1 · under PAR-24-100 | CHAKRABORTY, SUBHRA | JOHNS HOPKINS UNIVERSITY, MD | $762,838 | ZAI1 |
| 2025 | A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV1U01AI186860-01A1 · under PAR-24-100 | COLLINS, MATTHEWEDUPUGANTI, SRILATHATEIXEIRA, MAURO M | EMORY UNIVERSITY, GA | $578,157 | ZAI1 |
| 2025 | STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial1U01AI192033-01 · under PAR-24-100 | HEYSELL, SCOTT KMOORE, CHRISTOPHER CHARLES | UNIVERSITY OF VIRGINIA, VA | $361,931 | ZAI1 |
| 2025 | Cluster randomized trial of intermittent preventive treatment of malaria in school-agechildren to improve the health of students and decrease community transmission(CRITICal)1U01AI186861-01 · under PAR-21-083 | DORSEY, MATTHEW GNANKABIRWA, JOANITER IMMACULATE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $152,474 | ZAI1 |
| 2024 | Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial)1U01AI184071-01 · under PAR-21-083 | BLUMENTHAL, KIMBERLY GOLDKHAN, DAVID A | MASSACHUSETTS GENERAL HOSPITAL, MA | $3,234,536 | ZAI1 |
| 2024 | Controlling and Preventing Asthma Progression and Severity in Kids with Omalizumab Extension (PARK-EXT)1U01AI179563-01 · under PAR-21-083 | PHIPATANAKUL, WANDA | BOSTON CHILDREN'S HOSPITAL, MA | $2,250,000 | ZAI1 |
| 2024 | A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses1U01AI172800-01A1 · under PAR-21-083 | CHEW, KARA WDEEKS, STEVEN GRANTHARTIGAN-O'CONNOR, DENNIS J. | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $1,435,214 | ZAI1 |
| 2024 | Dupilumab in the Treatment of Pediatric Alopecia Areata1U01AI179629-01 · under PAR-21-083 | GUTTMAN, EMMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,419,216 | ZAI1 |
| 2024 | A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)1U01AI184159-01 · under PAR-21-083 | GILKESON, GARY SKAMEN, DIANE L | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $1,225,013 | ZAI1 |
| 2024 | Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage1U01AI184132-01 · under PAR-21-083 | AULETTA, JEFFERY JPULSIPHER, MICHAEL A | NATIONAL MARROW DONOR PROGRAM, MN | $1,072,951 | ZAI1 |
| 2024 | A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children1U01AI172733-01A1 · under PAR-21-083 | PICHICHERO, MICHAEL E | ROCHESTER GENERAL HOSPITAL (NY), NY | $822,233 | ZAI1 |
| 2023 | Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients1U01AI167799-01A1 · under PAR-21-083 | DANZIGER-ISAKOV, LARA AHALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $1,815,533 | ZAI1 |
| 2023 | A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana1U01AI179561-01 · under PAR-21-083 | KURITZKES, DANIEL R.LICHTERFELD, MATHIASSHAPIRO, ROGER L | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $1,799,067 | ZAI1 |
| 2023 | Kidney Transplantation from Donors with HIV: Impact on Rejection and Long-term Outcomes1U01AI177211-01 · under PAR-21-083 | DURAND, CHRISTINE MARIESEGEV, DORRY L. | JOHNS HOPKINS UNIVERSITY, MD | $1,781,226 | ZAI1 |
| 2023 | Safety and efficacy of Belatacept in heart transplantation1U01AI174997-01 · under PAR-21-083 | HABAL, MARLENA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $1,775,433 | ZAI1 |
| 2023 | Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia1U01AI165321-01A1 · under PAR-21-083 | CHU, CINDY S | UNIVERSITY OF OXFORD | $1,067,899 | ZAI1 |
| 2023 | First-in-human study of a potent anti-HBsAg neutralizing antibody1U01AI167786-01A1 · under PAR-21-083 | CASKEY, MARINA | ROCKEFELLER UNIVERSITY, NY | $864,658 | ZAI1 |
| 2023 | Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh1U01AI167788-01A1 · under PAR-21-083 | KORPE, POONUM S. | JOHNS HOPKINS UNIVERSITY, MD | $777,454 | ZAI1 |
| 2023 | Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection1U01AI174978-01 · under PAR-21-083 | RAJASINGHAM, RADHA | UNIVERSITY OF MINNESOTA, MN | $676,872 | ZAI1 |
| 2023 | A multicenter, randomized controlled trial of single and multiple dose regimes of oxfendazole for mild (one or two lesions) parenchymal brain cysticercosis1U01AI177191-01 · under PAR-21-083 | GARCIA, HECTOR HUGO | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $514,732 | ZAI1 |
| 2023 | A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis1U01AI155323-01A1 · under PAR-18-633 | CABADA, MIGUEL MAURICIOGARCIA, HECTOR HUGO | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $439,115 | ZAI1 |
| 2022 | Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD)1U01AI162463-01A1 · under PAR-21-083 | TAYLOR, STEVE MYER | DUKE UNIVERSITY, NC | $1,407,688 | ZAI1 |
| 2022 | Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru1U01AI157962-01A1 · under PAR-21-083 | HSIANG, MICHELLE SANG | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,293,493 | ZAI1 |
| 2022 | PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis1U01AI170426-01 · under PAR-21-083 | KOENIG, SERENA PATRICIAWASSERMAN, SEAN ADAM | BRIGHAM AND WOMEN'S HOSPITAL, MA | $1,221,014 | ZAI1 |
| 2022 | Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab1U01AI158460-01A1 · under PAR-21-083 | AHUJA, SUNIL K | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $1,182,367 | ZAI1 |
| 2022 | A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)1U01AI157931-01A1 · under PAR-21-083 | DURAND, CHRISTINE MARIESEGEV, DORRY L. | JOHNS HOPKINS UNIVERSITY, MD | $1,025,696 | ZAI1 |
| 2022 | Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania1U01AI155315-01A1 · under PAR-18-633 | HSIANG, MICHELLE SANG | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $936,110 | ZAI1 |
| 2022 | Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients1U01AI167789-01 · under PAR-21-083 | HALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $913,378 | ZAI1 |
| 2022 | Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults1U01AI155406-01A1 · under PAR-18-633 | PUSHKO, PETER M. | MEDIGEN, INC., MD | $709,235 | ZAI1 |
| 2022 | Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)1U01AI167784-01 · under PAR-21-083 | CROUSER, ELLIOTT DDAVIS, IAN CHRISTOPHER | OHIO STATE UNIVERSITY, OH | $576,575 | ZAI1 |
| 2021 | Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma1U01AI155299-01 · under PAR-18-633 | BERNARD, GORDON RAPHAELCAHILL, KATHERINE N | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $1,583,667 | ZAI1 |
| 2021 | Enhancing immunity to malaria in young children with effective chemoprevention1U01AI155325-01A1 · under PAR-18-633 | JAGANNATHAN, PRASANNA | STANFORD UNIVERSITY, CA | $1,283,030 | ZAI1 |
| 2021 | DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study1U01AI155300-01A1 · under PAR-18-633 | POSTELS, DOUGLAS | CHILDREN'S RESEARCH INSTITUTE, DC | $1,088,316 | ZAI1 |
| 2021 | Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.1U01AI162457-01 · under PAR-18-633 | DUNCAN, JOSEPH AHOBBS, MARCIA METZGAR | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $809,476 | ZAI1 |
| 2021 | Dietary and synbiotic strategy to limit gut microbiome dysbiosis and protect against Clostridioides difficile infection1U01AI150589-01A1 · under PAR-18-633 | LOZUPONE, CATHERINE | UNIVERSITY OF COLORADO DENVER, CO | $776,329 | ZAI1 |
| 2021 | Randomized trial of viral specific T-cell infusion to prevent viral infection after hematopoietic stem cell transplant.1U01AI157620-01 · under PAR-18-633 | DAVIES, STELLA MARGARETLUTZKO, CAROLYN M | CINCINNATI CHILDRENS HOSP MED CTR, OH | $663,928 | ZAI1 |
| 2020 | A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa1U01AI150510-01A1 · under PAR-18-633 | HAVLIR, DIANE VKAMYA, MOSES ROBERTPETERSEN, MAYA LIV | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $4,526,307 | ZAI1 |
| 2020 | Bacteriophage-based approach for managing Shigella infections1U01AI148054-01 · under PAR-18-633 | CHEN, WILBUR H.FRASER, CLAIRE M.KOTLOFF, KAREN L.SULAKVELIDZE, ALEXANDER | INTRALYTIX, INC., MD | $1,952,644 | ZAI1 |
| 2020 | INSPIRE (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients): The INSPIRE-ASP Trial for Intra-Abdominal and Skin and Soft Tissue Infections1U01AI153005-01 · under PAR-18-633 | HUANG, SUSAN S.PLATT, RICHARD | HARVARD PILGRIM HEALTH CARE, INC., MA | $1,646,462 | ZAI1 |
| 2020 | DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial1U01AI152980-01 · under PAR-18-633 | HORSBURGH, CHARLES ROBERTNAHID, PAYAM | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,470,699 | ZAI1 |
| 2020 | Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.1U01AI143493-01A1 · under PAR-18-633 | BARRY, EILEEN M.CHEN, WILBUR H. | UNIVERSITY OF MARYLAND BALTIMORE, MD | $1,391,457 | ZAI1 |
| 2020 | Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases1U01AI148069-01 · under PAR-18-633 | VAZQUEZ PROKOPEC, GONZALO MARTIN | EMORY UNIVERSITY, GA | $1,385,938 | ZAI1 |
| 2020 | Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects1U01AI141310-01A1 · under PAR-18-633 | BILSEL, PAMUK | FLUGEN, INC., WI | $1,311,111 | ZAI1 |
| 2020 | Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda1U01AI141308-01A1 · under PAR-18-633 | DORSEY, MATTHEW GROSENTHAL, PHILIP JON | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,194,675 | ZAI1 |
| 2020 | Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure1U01AI152969-01 · under PAR-18-633 | RIDDLER, SHARON | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $1,173,561 | ZAI1 |
| 2020 | Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals1U01AI152961-01 · under PAR-18-633 | CHAISSON, RICHARD E. | JOHNS HOPKINS UNIVERSITY, MD | $916,330 | ZAI1 |
| 2020 | Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients1U01AI152967-01 · under PAR-18-633 | HALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $862,770 | ZAI1 |
| 2020 | A Phase I Randomized Clinical Trial of a Novel Mucosal Recombinant H5 Influenza Vaccine with Nanoemulsion Adjuvant Followed by Parenteral Boost of Licensed Inactivated Influenza A H5N1 Vaccine1U01AI148081-01 · under PAR-18-633 | ORTIZ, JUSTIN R. | UNIVERSITY OF MARYLAND BALTIMORE, MD | $769,127 | ZAI1 |
| 2020 | A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa1U01AI150508-01A1 · under PAR-18-633 | HEYSELL, SCOTT KMOORE, CHRISTOPHER CHARLES | UNIVERSITY OF VIRGINIA, VA | $682,830 | ZAI1 |
| 2019 | Intervention to Reduce Early (Peanut) Allergy in Children (iREACH)1U01AI138907-01A1 · under PAR-18-633 | GUPTA, RUCHI S | LURIE CHILDREN'S HOSPITAL OF CHICAGO, IL | $1,597,100 | ZAI1 |
| 2019 | Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma1U01AI143514-01 · under PAR-18-633 | CHATILA, TALAL AMINEPHIPATANAKUL, WANDA | BOSTON CHILDREN'S HOSPITAL, MA | $1,458,175 | ZAI1 |
| 2019 | A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population1U01AI134582-01A1 · under PAR-18-633 | KIRKPATRICK, BETH DIANE | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $1,300,717 | ZAI1 |
| 2019 | Extended follow-up of randomized participants in the INSIGHT START trial1U01AI136780-01 · under PAR-16-270 | NEATON, JAMES DENNIS | UNIVERSITY OF MINNESOTA, MN | $1,119,517 | ZHL1 |
| 2019 | "NextGen Long-acting Platform: Targeted Combination Antiretrovirals"1U01AI148055-01 · under PAR-18-633 | COLLIER, ANN CORNWALLHO, RODNEY J.Y. | UNIVERSITY OF WASHINGTON, WA | $794,929 | ZAI1 |
| 2019 | Trial of Metformin for TB/HIV Host-directed Therapy1U01AI134585-01A1 · under PAR-18-633 | KORNFELD, HARDYSINGHAL, AMITWALLIS, ROBERT S | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $571,971 | ZAI1 |
| 2018 | Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab1U01AI136816-01 · under PAR-16-270 | MADSEN, JOREN C | MASSACHUSETTS GENERAL HOSPITAL, MA | $3,029,663 | ZAI1 |
| 2018 | HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation1U01AI138897-01 · under PAR-16-270 | DURAND, CHRISTINE MARIESEGEV, DORRY L. | JOHNS HOPKINS UNIVERSITY, MD | $1,778,541 | ZAI1 |
| 2018 | Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment1U01AI116400-01A1 · under PAR-16-270 | MILLER, LOREN G. | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $1,186,965 | ZAI1 |
| 2018 | New chemotherapy regimens and biomarkers for Chagas disease1U01AI129783-01A1 · under PAR-16-270 | ALMEIDA, IGOR CGASCON, JOAQUIMTORRICO, FAUSTINO | UNIVERSITY OF TEXAS EL PASO, TX | $1,181,878 | ZAI1 |
| 2018 | Selective CD28 Blockade in Renal Transplant Recipients1U01AI138909-01 · under PAR-16-270 | ADAMS, ANDREW BFORD, MANDY LLARSEN, CHRISTIAN P. | EMORY UNIVERSITY, GA | $1,135,202 | ZAI1 |
| 2018 | Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients1U01AI125053-01A1 · under PAR-13-151 | SAFDAR, NASIA | UNIVERSITY OF WISCONSIN-MADISON, WI | $1,126,433 | ZAI1 |
| 2018 | Regulatory Dendritic Cell Therapy in Live Donor Renal Transplant Recipients1U01AI136779-01 · under PAR-16-270 | THOMSON, ANGUS W | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $1,000,075 | ZAI1 |
| 2018 | Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria1U01AI138910-01 · under PAR-16-270 | FOY, BRIAN DAVIDPARIKH, SUNIL | COLORADO STATE UNIVERSITY, CO | $745,773 | ZAI1 |
| 2018 | A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus1U01AI125159-01A1 · under PAR-16-270 | GILKESON, GARY S | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $720,193 | ZAI1 |
| 2017 | HOPE in Action: A clinical trial of HIV-to-HIV deceased donor kidney transplantation1U01AI134591-01 · under PAR-16-270 | DURAND, CHRISTINE MARIESEGEV, DORRY L. | JOHNS HOPKINS UNIVERSITY, MD | $1,578,717 | ZAI1 |
| 2017 | Low-dose IL-2 in Established T1D1U01AI125057-01A1 · under PAR-16-270 | MALEK, THOMAS RPUGLIESE, ALBERTOSKYLER, JAY S | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $1,529,390 | ZAI1 |
| 2017 | High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients1U01AI132004-01 · under PAR-16-270 | HALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $832,698 | ZAI1 |
| 2017 | 3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir1U01AI129825-01 · under PAR-13-151 | CASKEY, MARINA | ROCKEFELLER UNIVERSITY, NY | $819,850 | ZAI1 |
| 2017 | Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists1U01AI129789-01 · under PAR-13-151 | BETHONY, JEFFREY MICHAELDIEMERT, DAVID JOSEPH | GEORGE WASHINGTON UNIVERSITY, DC | $797,494 | ZAI1 |
| 2017 | MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa1U01AI131861-01 · under PAR-16-270 | GINSBERG, ANN MHATHERILL, MARK | AERAS, MD | $210,000 | ZAI1 |
| 2016 | Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients1U01AI125135-01 · under PAR-13-151 | HALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $1,711,635 | ZAI1 |
| 2016 | Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector1U01AI125051-01 · under PAR-13-151 | PAI, SUNG-YUN | BOSTON CHILDREN'S HOSPITAL, MA | $1,132,346 | ZAI1 |
| 2016 | Cadaveric Donor Lung and Bone Marrow Transplantation in Immunodeficiency Diseases1U01AI125050-01 · under PAR-13-151 | MCDYER, JOHN FSZABOLCS, PAUL | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $959,096 | ZAI1 |
| 2016 | Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans1U01AI125056-01 · under PAR-13-151 | TURNER, RONALD B.WOODFOLK, JUDITH A | UNIVERSITY OF VIRGINIA, VA | $898,658 | ZAI1 |
| 2015 | School Inner-City Asthma Intervention Study1U01AI110397-01A1 · under PAR-13-151 | PHIPATANAKUL, WANDA | BOSTON CHILDREN'S HOSPITAL, MA | $1,743,949 | ZAI1 |
| 2015 | Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients1U01AI118594-01 · under PAR-13-151 | STOCK, PETER G | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,670,008 | ZAI1 |
| 2015 | Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?1U01AI118506-01 · under PAR-13-151 | SHAIKH, NADERWALD, ELLEN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $1,021,834 | ZAI1 |
| 2015 | 3BNC117 mAb in HIV-infected subjects on combination ART1U01AI118536-01 · under PAR-13-151 | CASKEY, MARINA | ROCKEFELLER UNIVERSITY, NY | $840,281 | ZAI1 |
| 2015 | Experimental human infection with isogenic mutants of Neisseria gonorrhoeae1U01AI114378-01A1 · under PAR-13-151 | HOBBS, MARCIA METZGAR | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $701,174 | ZAI1 |
| 2015 | Phase 1 Trial of Na-APR-1 and Na-GST-1 Hookworm Vaccines in Brazilian Adults1U01AI116414-01 · under PAR-13-151 | DIEMERT, DAVID JOSEPH | GEORGE WASHINGTON UNIVERSITY, DC | $675,140 | ZAI1 |
| 2015 | Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adults1U01AI112367-01 · under PAR-13-151 | PLOWE, CHRISTOPHER V. | UNIVERSITY OF MARYLAND BALTIMORE, MD | $661,033 | ZAI1 |
| 2015 | Cell Phone Video Directly Observed Therapy to Monitor Short Course LTBI Treatment1U01AI116392-01 · under PAR-13-151 | GARFEIN, RICHARD S | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $648,715 | ZAI1 |
| 2015 | Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa1U01AI110435-01A1 · under PAR-13-151 | REED, SHARON L | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $629,075 | ZAI1 |
| 2014 | Towards Eradication: Reducing Proviral HIV DNA with Interferon-a Immunotherapy1U01AI110434-01 · under PAR-13-151 | MONTANER, LUIS J | WISTAR INSTITUTE, PA | $1,708,367 | ZAI1 |
| 2014 | Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation1U01AI110658-01 · under PAR-13-151 | BLUESTONE, JEFFREY AFENG, SANDYKANG, SANG-MOTANG, QIZHI | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $983,209 | ZAI1 |
| 2014 | Early Infant Treatment1U01AI114235-01 · under PAR-13-151 | KURITZKES, DANIEL R.LICHTERFELD, MATHIASSHAPIRO, ROGER L | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $979,999 | ZHD1 |
| 2014 | Searching for Persistence in Lyme Disease1U01AI109656-01A1 · under PAR-13-151 | HU, LINDEN T | TUFTS MEDICAL CENTER, MA | $817,356 | ZAI1 |
| 2014 | Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation1U01AI110410-01 · under PAR-13-151 | MACATANGAY, BERNARD JONAS CRIDDLER, SHARON | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $640,365 | ZAI1 |
| 2014 | Randomized Controlled Trial of Treatment of Male Partners of Women with BV1U01AI108509-01A1 · under PAR-13-151 | SCHWEBKE, JANE R. | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $615,470 | ZAI1 |
| 2014 | Nikkomycin Z treatment of primary pneumonia due to Coccidioides1U01AI112406-01 · under PAR-13-151 | LARWOOD, DAVID | VALLEY FEVER SOLUTIONS, INC., AZ | $211,459 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.